Drug Profile
Research programme: Delta-like ligand 4 inhibitors - AbbVie
Alternative Names: ABT-487; Delta-like ligand 4 inhibitorsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class
- Mechanism of Action DLL4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 21 Oct 2011 Preclinical trials in Cancer in USA (unspecified route)